Myeloid Leukemia, Chronic
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
CML patients in both blast crisis (BC) and the accelerated phase (AP) had significantly higher PRAME levels than CML patients in the chronic phase (CP) (p = 0.006 and 0.0461, respectively).
|
24008770 |
2013 |
Myeloid Leukemia, Chronic
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
In contrast, PRAME and WT1 were more highly expressed by all CML CD34(+) subsets than their normal counterparts.
|
21132730 |
2011 |
Myeloid Leukemia, Chronic
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate that PRAME, but not EZH2, is upregulated in BCR-ABL cells and is associated with the progression of disease in CML patients.
|
20838376 |
2011 |
Myeloid Leukemia, Chronic
|
0.380 |
Biomarker
|
disease |
BEFREE |
PRAME CTLs or vaccines may thus be of value for patients with CML.
|
18591381 |
2008 |
Myeloid Leukemia, Chronic
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Twenty-four of 70 (34%) cases with CML/CMPD and 5 of 18 (28%) cases with CLL showed PRAME expression.
|
16914202 |
2007 |
Myeloid Leukemia, Chronic
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that hypomethylation of PRAME up-regulates its expression in CML and might play a significant role in the progression of the disease.
|
17382387 |
2007 |
Myeloid Leukemia, Chronic
|
0.380 |
Biomarker
|
disease |
CTD_human |
Several LAAs are expressed in CML and therefore are candidate structures for specific immunotherapies: bcr-abl (100%), G250 (24%), hTERT (53%), MPP11 (91%), NEWREN60 (94%), PRAME (62%), Proteinase3 (71%), RHAMM/CD168 (83%), and WT1 (53%), but not BAGE, MAGE-A1, SSX2, or NY-ESO-1.
|
17157168 |
2006 |
Myeloid Leukemia, Chronic
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Several LAAs are expressed in CML and therefore are candidate structures for specific immunotherapies: bcr-abl (100%), G250 (24%), hTERT (53%), MPP11 (91%), NEWREN60 (94%), PRAME (62%), Proteinase3 (71%), RHAMM/CD168 (83%), and WT1 (53%), but not BAGE, MAGE-A1, SSX2, or NY-ESO-1.
|
17157168 |
2006 |
Myeloid Leukemia, Chronic
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Moreover, comparison of PRAME expression among CD34+ cells with CML in blastic, accelerated, and chronic phases revealed a higher expression in CML in advanced phases.
|
10682862 |
2000 |